^
Association details:
| Biomarker: | DDR |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
Published date:
07/12/2021
Excerpt:
DDR mutation was an independent prognostic factor for survival analysis of advanced PDAC patients (p = 0.032). For DDR mutant patients, treatment with platinum-based chemotherapy (p = 0.0096) or olaparib (p = 0.018) respectively improved the overall survival....In the 18 advanced DDR-mutated patients, 4 patients received the second-line olaparib treatment after the failure of chemotherapy with gemcitabine and nab-paclitaxel or platinum. An improvement of OS was observed in the group with olaparib treatment compared to those without (p = 0.034; Fig. 5B).
DOI:
10.1186/s12967-021-02972-6
Source:
Title:
Germline and somatic DNA damage repair gene mutations potentially predict the efficacy of relevant treatment in Chinese patients with pancreatic ductal adenocarcinoma.
Published date:
05/28/2020
Excerpt:
No significant improvement of OS existed between patients with or without DDR mutations (p = 0.88). Treatment with olaparib (adjusted HR, 0.2550; P = 0.0720) or platinum-based chemotherapy (adjusted HR, 0.1308; P = 0.0185) respectively decreased hazard of death in patients with DDR mutation....We found the potential role of germline and somatic DDR mutation status in predicting the response to olaparib and platinum-based chemotherapy, especially with BRCA or ATM mutation.
DOI:
10.1200/JCO.2020.38.15_suppl.e16732
